ThinPrep Screen with HPV for Women 30 Years and Older
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
The majority (>99%) of cervical epithelial neoplasms are the result of human papillomavirus (HPV) infection. "High-risk'' HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) can result in both low-grade squamous intraepithelial lesions (LSIL) and high-grade squamous intraepithelial lesions (HSIL), as well as invasive carcinomas.(1,2) Patients with both a negative cytology and negative HPV have been shown to be at extremely low risk for cervical neoplasia.(1,2)
For women 30 years old and older who have received a negative Pap test and concurrent negative HPV result, the American Cancer Society (ACS) and American College of Obstetricians and Gynecologists (ACOG) recommendations for cervical screening state that physicians may lengthen the screening interval to 3 years when using the combined test. Patients deemed to be high-risk by the clinician should still be screened more frequently.
The presence of high risk HPV types in cervical specimens identifies a subgroup of patients with a greater likelihood of having a high grade squamous intraepithelial lesion. Current guidelines for follow up of a cytology-negative/HPV-positive patient recommend repeat HPV testing in 12 months.(2)
Detection of cervical carcinoma or intraepithelial lesions and the presence or absence of high-risk HPV when screening women over the age of 30 for possible cervical neoplasia
Standard reporting, as defined by the Bethesda System (TBS) is utilized.
A positive HPV test result indicates the presence of 1 or more of the high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 58, 59, or 68).
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
A negative HPV test or Pap smear result does not preclude the presence of carcinoma or intraepithelial lesion; false-negative rates of the Pap test range from 15% to 30%; the false-negative rate of the HPV test (Digene, Hybrid Capture II) is 1.1% to 7.5%.(1,4)
This test is not recommended for patients less than 30 years of age due to the transient nature of the HPV virus in younger patients; test 83342 ThinPrep Screen with Human Papillomavirus (HPV) Reflex is available for women under the age of 30 with pap tests diagnosed as ASCUS.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
ThinPrep PAP Test Screen:
Satisfactory for evaluation. Negative for intraepithelial lesion or malignancy.
High Risk HPV DNA Detection:
Negative for types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68
Clinical References Provides recommendations for further in-depth reading of a clinical nature
1. Lorincz AT, Richart RM: Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 2003 August;127(8):959-968
2. Wright TC, Jr, Schiffman M: Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 2003 February 6;348(6):489-490
3. Soloman D, Davey D, Kurman R, et al: The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002 April;287(16):2114-2119
4. Sherman ME, Lorincz A, Scott DR, et al: Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Nat Cancer Inst 2003 January;95(1):46-52